GAO Report Finds Lapses in FDA Postmarket Data for Expedited Drugs

Drug Industry Daily
A A
While the FDA is speeding many drugs to the market, the agency lacks reliable, accessible data needed to conduct systematic oversight and meet postmarket safety reporting responsibilities, says a GAO report released Thursday.

To View This Article:

Login

Subscribe To Drug Industry Daily